全文获取类型
收费全文 | 6111篇 |
免费 | 382篇 |
国内免费 | 16篇 |
专业分类
耳鼻咽喉 | 84篇 |
儿科学 | 591篇 |
妇产科学 | 104篇 |
基础医学 | 738篇 |
口腔科学 | 117篇 |
临床医学 | 368篇 |
内科学 | 1189篇 |
皮肤病学 | 290篇 |
神经病学 | 307篇 |
特种医学 | 221篇 |
外科学 | 591篇 |
综合类 | 289篇 |
一般理论 | 3篇 |
预防医学 | 355篇 |
眼科学 | 214篇 |
药学 | 510篇 |
中国医学 | 21篇 |
肿瘤学 | 517篇 |
出版年
2023年 | 38篇 |
2022年 | 88篇 |
2021年 | 204篇 |
2020年 | 138篇 |
2019年 | 160篇 |
2018年 | 198篇 |
2017年 | 117篇 |
2016年 | 143篇 |
2015年 | 153篇 |
2014年 | 257篇 |
2013年 | 288篇 |
2012年 | 376篇 |
2011年 | 368篇 |
2010年 | 219篇 |
2009年 | 197篇 |
2008年 | 269篇 |
2007年 | 256篇 |
2006年 | 253篇 |
2005年 | 233篇 |
2004年 | 198篇 |
2003年 | 170篇 |
2002年 | 151篇 |
2001年 | 157篇 |
2000年 | 120篇 |
1999年 | 121篇 |
1998年 | 69篇 |
1997年 | 60篇 |
1996年 | 62篇 |
1995年 | 33篇 |
1994年 | 51篇 |
1993年 | 39篇 |
1992年 | 88篇 |
1991年 | 96篇 |
1990年 | 97篇 |
1989年 | 84篇 |
1988年 | 77篇 |
1987年 | 80篇 |
1986年 | 61篇 |
1985年 | 68篇 |
1984年 | 65篇 |
1983年 | 49篇 |
1982年 | 65篇 |
1981年 | 77篇 |
1980年 | 73篇 |
1979年 | 55篇 |
1978年 | 36篇 |
1977年 | 27篇 |
1976年 | 33篇 |
1973年 | 31篇 |
1970年 | 26篇 |
排序方式: 共有6509条查询结果,搜索用时 31 毫秒
101.
Stimulation of adrenergic activity by desipramine enhances hematopoietic stem and progenitor cell mobilization along with G‐CSF in multiple myeloma: A pilot study
下载免费PDF全文
![点击此处可从《American journal of hematology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Aditi Shastri Anjali Budhathoki Stefan K. Barta Noah Kornblum Olga Derman Ramakrishna Battini Radha Raghupathy Amit K. Verma Paul S. Frenette Ira Braunschweig Murali Janakiram 《American journal of hematology》2017,92(10):1047-1051
Hematopoietic stem cell (HSC) release is positively regulated by the sympathetic nervous system through the β3 adrenergic receptor. Preclinical studies have demonstrated that the combination of desipramine and G‐CSF resulted in improved HSC mobilization. Here, we present the results of an open‐label single‐arm pilot study in patients with multiple myeloma undergoing autologous stem cell transplantation (ASCT) to assess the safety and efficacy of desipramine combined with G‐SCF to induce HSC mobilization. The primary endpoint was safety of the combination including engraftment kinetics. The secondary endpoint was the proportion of patients who collected ≥5 × 106 CD34+ cells/kg. Outcomes were compared with historical matched controls during the same time period with multiple myeloma mobilized with G‐CSF. All study patients received desipramine 100 mg daily for 7 days, starting 4 days prior to G‐CSF administration (D‐3) and continued taking it along with G‐CSF for a total of 7 days. Six of ten patients enrolled completed the protocol with minimal side effects. All of them achieved the target collection of 5 × 106 CD34 cells/kg in a median of 1.5 apheresis session with two patients needing additional plerixafor (16%), while 11 out of 13 patients (85%) achieved the target of 5 × 106 CD34 cells/kg in the historical control group in a median of 2 apheresis procedures and seven patients needed plerixafor (54%). The combination of desipramine and G‐CSF is safe and signals improved mobilization over G‐CSF alone, providing a possible alternative means of mobilization that needs further investigation. 相似文献
102.
103.
104.
Ashutosh Verma James Matsunaga Sergey Artiushin Marija Pinne Dirk J. Houwers David A. Haake Brian Stevenson John F. Timoney 《Clinical and Vaccine Immunology : CVI》2012,19(3):452-456
Screening of an expression library of Leptospira interrogans with eye fluids from uveitic horses resulted in identification of a novel protein, LruC. LruC is located in the inner leaflet of the leptospiral outer membrane, and an lruC gene was detected in all tested pathogenic L. interrogans strains. LruC-specific antibody levels were significantly higher in eye fluids and sera of uveitic horses than healthy horses. These findings suggest that LruC may play a role in equine leptospiral uveitis. 相似文献
105.
106.
A.A. Gupta X. Yao S. Verma H. Mackay L. Hopkins 《Clinical oncology (Royal College of Radiologists (Great Britain))》2013,25(6):346-355
The goal of this systematic review was to investigate and compare the treatment effects of systemic chemotherapy (i.e. doxorubicin, gemcitabine, gemcitabine plus docetaxel, or trabectedin) in women with inoperable, locally advanced, recurrent, or metastatic uterine leiomyosarcoma. A 2005 systematic review (searching the literature from 1980 to June 2004) on systemic therapy in advanced uterine sarcoma was used as the basis for this updated review. MEDLINE and EMBASE (from January 2004 to June 2011), the Cochrane Library, some main guideline websites and the American Society of Clinical Oncology and the Connective Tissue Oncology Society annual meeting abstracts were searched. One arm from a randomised controlled trial (RCT), four single-arm phase II trials and one abstract were included in this systematic review. The studies of gemcitabine plus docetaxel have reported numerically longer median overall survival (14.7–17.9 months versus 12.1 months) and numerically higher objective response rates (27–53% versus 25%) than those reported in the study of doxorubicin alone. The combination of gemcitabine plus docetaxel resulted in more toxicity than doxorubicin alone. The available study for single-agent gemcitabine reported a tumour response rate of 21%, which is not superior to the 25% response rate with doxorubicin alone. One abstract (pooling data from two RCTs) failed to show the superiority of gemcitabine plus docetaxel over gemcitabine alone for tumour response rate (23% versus 18%) and progression-free survival (6 versus 4.9 months). To date, there is insufficient evidence to support or refute the use of trabectedin in the target patients. Doxorubicin, gemcitabine, and gemcitabine plus docetaxel are treatment options in women with inoperable, locally advanced, recurrent, or metastatic uterine leiomyosarcoma as first- or second-line therapy. Well-designed and good-quality RCTs are required to investigate the efficacy of chemotherapy and quality of life in target patients with uterine leiomyosarcoma. 相似文献
107.
108.
109.
110.